SubHero Banner

Margenza (margetuximab-cmkb) – New drug approval

On December 16, 2020 - MacroGenics announced the FDA approval of Margenza (margetuximab-cmkb), in combination with chemotherapy, for the treatment of adult patients with metastatic human epidermal growth factor receptor 2 protein (HER2)-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.

Download PDF